<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050151</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1607</org_study_id>
    <nct_id>NCT03050151</nct_id>
  </id_info>
  <brief_title>Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis</brief_title>
  <official_title>An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect data on actual-use to assess technical performance and user injections of
      dupilumab auto-injection device by patients with atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study is conducted in 2 parts: part A and part B.

      Part A - Patients with moderate-to-severe AD will be randomized to receive dupilumab (dose 1)
      by auto-injector (AI) device or prefilled syringe.

      Once part A is completely enrolled, part B will randomize patients with moderate-to-severe AD
      to receive dupilumab (dose 2) by auto-injector (AI) device or prefilled syringe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Actual">February 12, 2018</completion_date>
  <primary_completion_date type="Actual">November 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of validated AI device-associated product technical failures (PTFs) during the treatment period divided by total number of actual injections</measure>
    <time_frame>To week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of validated AI device-associated PTFs during the treatment period divided by total number of actual injections.</measure>
    <time_frame>To week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an AI device-associated PTF</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with an AI device-associated PTF</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AI device-associated product technical complaints (PTCs) divided by total number of actual injections</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of AI device-associated PTCs divided by total number of actual injections</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an AI device-associated PTC</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with an AI device-associated PTC</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an AI device-associated failure to deliver dose</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with an AI device-associated failure to deliver dose</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with response to patient satisfaction questions with the AI device</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with response to patient satisfaction questions with the AI device</measure>
    <time_frame>To week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Atopic Disorders</condition>
  <condition>Eczema, Atopic</condition>
  <arm_group>
    <arm_group_label>1 - Dupilumab (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose (dose 1) as per protocol delivered by auto-injector device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Dupilumab (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose (dose 1) as per protocol delivered by prefilled syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 - Dupilumab (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose (dose 2) as per protocol delivered by auto-injector device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 - Dupilumab (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose (dose 2) as per protocol delivered by prefilled syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe</description>
    <arm_group_label>1 - Dupilumab (Part A)</arm_group_label>
    <arm_group_label>2 - Dupilumab (Part A)</arm_group_label>
    <arm_group_label>3 - Dupilumab (Part B)</arm_group_label>
    <arm_group_label>4 - Dupilumab (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auto-injector Device</intervention_name>
    <description>Delivery of Dupilumab by auto-injector device</description>
    <arm_group_label>1 - Dupilumab (Part A)</arm_group_label>
    <arm_group_label>3 - Dupilumab (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prefilled syringe</intervention_name>
    <description>Delivery of Dupilumab by prefilled syringe</description>
    <arm_group_label>2 - Dupilumab (Part A)</arm_group_label>
    <arm_group_label>4 - Dupilumab (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Diagnosis of chronic atopic dermatitis for at least 3 years with inadequate response
             to topical medications within 6 months before screening

          2. Willing and able to comply with all clinic visits and study-related procedures

          3. Provide signed informed consent

        Key Exclusion Criteria:

          1. Patient &lt; 30.0 kilograms (Kg) in weight

          2. Patient who has previously participated in a dupilumab clinical study

          3. Patient who has been treated with the following:

               -  An investigational drug within 8 weeks or within 5 half-lives (if
                  known),whichever is longer, before the baseline visit

               -  Immunosuppressive/ immunomodulating drugs (e.g., systemic corticosteroids,
                  cyclosporine, mycophenolate-mufti, IFN-γ, Janus kinase inhibitors, azathioprine,
                  methotrexate, etc.) or Phototherapy for AD within 4 weeks before the baseline
                  visit

               -  An experimental monoclonal antibody within 5 half-lives or within 6◦months prior
                  to visit 1 if the half-life is unknown

               -  Biologic agents within 5 half-lives (if known) or 16 weeks prior to baseline
                  visit, whichever is longer

               -  Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to visit 1

               -  A live (attenuated) vaccine within 4 weeks before the baseline visit

          4. Patient who has initiated treatment with prescription moisturizers or moisturizers
             containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation
             products during the screening period (patients may continue using stable doses of such
             moisturizers if initiated before the screening visit)

          5. Patient who has skin comorbidities that may interfere with study assessments

          6. Patient with a planned or anticipated major surgical procedure during the patient's
             participation in this study

          7. Women of childbearing potential unwilling to use adequate birth control measures
             during the study

          8. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed
             during the study

        Note: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Corning</city>
        <state>New York</state>
        <zip>14830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

